STOCK TITAN

[D] Cybin Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
D
Rhea-AI Filing Summary

Cybin Inc. (CYBN) filed a Form D announcing the completion of a Rule 506(b) private placement. The Ontario-based psychedelic therapeutics company sold $50 million in a mix of debt securities, warrants/options, and underlying shares. The first sale occurred on 30 June 2025 and the offering will not extend beyond one year. All of the targeted amount has been placed, leaving $0 remaining.

Key terms

  • Total offering size: $50,000,000
  • Securities type: Debt plus equity-linked instruments
  • Number of investors: 1 (accredited status not disclosed)
  • Sales commissions: $2,670,000 (Joseph Gunnar & Co., LLC)
  • Finder’s fees: $0
  • Proceeds earmarked for insiders: $0

The issuer declined to disclose revenue or asset size. The financing adds fresh capital without immediate payments to executives or directors and is not tied to a merger or acquisition. The exemption selected (Rule 506(b)) restricts general solicitation and requires sales only to accredited investors or up to 35 non-accredited sophisticated purchasers.

Cybin Inc. (CYBN) ha presentato un Modulo D annunciando il completamento di un collocamento privato secondo la Regola 506(b). La società canadese con sede in Ontario specializzata in terapie psichedeliche ha venduto 50 milioni di dollari attraverso un mix di strumenti di debito, warrant/opzioni e azioni sottostanti. La prima vendita è avvenuta il 30 giugno 2025 e l'offerta non si estenderà oltre un anno. L'intero importo previsto è stato collocato, lasciando un residuo pari a 0 dollari.

Termini chiave

  • Dimensione totale dell'offerta: 50.000.000 dollari
  • Tipologia di strumenti: debito e strumenti collegati all'equity
  • Numero di investitori: 1 (stato accreditato non rivelato)
  • Commissioni di vendita: 2.670.000 dollari (Joseph Gunnar & Co., LLC)
  • Commissioni per intermediari: 0 dollari
  • Proventi destinati a insider: 0 dollari

L'emittente non ha rivelato dati su ricavi o patrimonio. Il finanziamento introduce nuovo capitale senza pagamenti immediati a dirigenti o amministratori ed è non collegato a fusioni o acquisizioni. L'esenzione scelta (Regola 506(b)) limita la sollecitazione generale e prevede vendite solo a investitori accreditati o fino a 35 acquirenti sofisticati non accreditati.

Cybin Inc. (CYBN) presentó un Formulario D anunciando la finalización de una colocación privada bajo la Regla 506(b). La empresa de terapias psicodélicas con sede en Ontario vendió 50 millones de dólares mediante una combinación de valores de deuda, warrants/opciones y acciones subyacentes. La primera venta tuvo lugar el 30 de junio de 2025 y la oferta no se extenderá más allá de un año. Se ha colocado la totalidad del monto objetivo, quedando 0 dólares restantes.

Términos clave

  • Tamaño total de la oferta: 50.000.000 dólares
  • Tipo de valores: deuda e instrumentos vinculados a capital
  • Número de inversores: 1 (estatus acreditado no revelado)
  • Comisiones de venta: 2.670.000 dólares (Joseph Gunnar & Co., LLC)
  • Honorarios de intermediarios: 0 dólares
  • Fondos destinados a personas internas: 0 dólares

El emisor no divulgó ingresos ni tamaño de activos. La financiación aporta capital fresco sin pagos inmediatos a ejecutivos o directores y no está vinculada a una fusión o adquisición. La exención seleccionada (Regla 506(b)) restringe la solicitud general y requiere ventas solo a inversores acreditados o hasta 35 compradores sofisticados no acreditados.

Cybin Inc. (CYBN)은 Rule 506(b) 사모 발행 완료를 알리는 Form D를 제출했습니다. 온타리오에 본사를 둔 사이키델릭 치료제 회사는 채무 증권, 워런트/옵션, 기초 주식을 혼합하여 5,000만 달러를 판매했습니다. 첫 판매는 2025년 6월 30일에 이루어졌으며, 공모는 1년을 초과하지 않습니다. 목표 금액 전액이 배정되어 남은 금액은 0달러입니다.

주요 조건

  • 총 공모 규모: 50,000,000달러
  • 증권 유형: 부채 및 주식 연계 상품
  • 투자자 수: 1명 (인증 상태 미공개)
  • 판매 수수료: 2,670,000달러 (Joseph Gunnar & Co., LLC)
  • 중개 수수료: 0달러
  • 내부자 배정 수익: 0달러

발행사는 매출이나 자산 규모를 공개하지 않았습니다. 이번 자금 조달은 경영진이나 이사에게 즉각적인 지급 없이 신규 자본을 추가하며, 합병이나 인수와 관련이 없습니다. 선택된 면제 조항(Rule 506(b))은 일반 모집을 제한하며, 인증 투자자 또는 최대 35명의 비인증 고급 투자자에게만 판매를 허용합니다.

Cybin Inc. (CYBN) a déposé un formulaire D annonçant la clôture d’un placement privé selon la règle 506(b). La société de thérapeutiques psychédéliques basée en Ontario a vendu 50 millions de dollars via un mélange de titres de dette, bons de souscription/options et actions sous-jacentes. La première vente a eu lieu le 30 juin 2025 et l’offre ne s’étendra pas au-delà d’un an. La totalité du montant ciblé a été placée, il reste donc 0 dollar.

Principaux termes

  • Taille totale de l’offre : 50 000 000 dollars
  • Type de titres : dette et instruments liés aux actions
  • Nombre d’investisseurs : 1 (statut accrédité non divulgué)
  • Commissions de vente : 2 670 000 dollars (Joseph Gunnar & Co., LLC)
  • Frais d’apporteurs d’affaires : 0 dollar
  • Produit destiné aux initiés : 0 dollar

L’émetteur a refusé de divulguer ses revenus ou la taille de ses actifs. Ce financement apporte de nouveaux capitaux sans paiements immédiats aux cadres ou administrateurs et n’est pas lié à une fusion ou acquisition. L’exemption choisie (règle 506(b)) restreint la sollicitation générale et exige des ventes uniquement aux investisseurs accrédités ou à un maximum de 35 acheteurs sophistiqués non accrédités.

Cybin Inc. (CYBN) hat ein Formular D eingereicht und die Durchführung einer Privatplatzierung nach Regel 506(b) bekanntgegeben. Das in Ontario ansässige Unternehmen für psychedelische Therapien verkaufte 50 Millionen US-Dollar in einer Mischung aus Schuldtiteln, Warrants/Optionen und zugrunde liegenden Aktien. Der erste Verkauf erfolgte am 30. Juni 2025, und das Angebot wird nicht länger als ein Jahr laufen. Der gesamte Zielbetrag wurde platziert, es verbleiben 0 US-Dollar.

Wichtige Bedingungen

  • Gesamtvolumen des Angebots: 50.000.000 US-Dollar
  • Art der Wertpapiere: Schulden plus aktiengebundene Instrumente
  • Anzahl der Investoren: 1 (Status akkreditiert nicht angegeben)
  • Verkaufsprovisionen: 2.670.000 US-Dollar (Joseph Gunnar & Co., LLC)
  • Vermittlungsgebühren: 0 US-Dollar
  • Erträge für Insider: 0 US-Dollar

Der Emittent verweigerte Angaben zu Umsatz oder Vermögenswerten. Die Finanzierung bringt frisches Kapital ohne sofortige Zahlungen an Führungskräfte oder Direktoren und ist nicht an eine Fusion oder Übernahme gebunden. Die gewählte Befreiung (Regel 506(b)) schränkt die allgemeine Werbung ein und erlaubt Verkäufe nur an akkreditierte Investoren oder bis zu 35 nicht akkreditierte, aber versierte Käufer.

Positive
  • $50 million in gross proceeds secured, bolstering Cybin’s cash position for ongoing development.
  • No insider payments disclosed, reducing potential conflicts of interest.
  • Reasonable commission rate of roughly 5.3%, indicating cost-effective capital raising.
Negative
  • Financing includes debt and warrant components, introducing leverage and future equity dilution.
  • Single-investor structure concentrates ownership and negotiation power.
  • Company declined to disclose revenue, limiting visibility into leverage capacity.

Insights

TL;DR: Cybin secures $50 M via private debt + warrants, strengthening liquidity but adding leverage and potential dilution.

The completed $50 million raise delivers meaningful cash for R&D and clinical programs without immediate insider payouts. Using debt alongside warrants implies future dilution and interest expense, but avoids an all-equity raise that could have pressured the share price today. A single investor simplifies negotiations yet concentrates counter-party risk. At 5.3% (2.67/50) selling cost, placement expenses are reasonable for a Rule 506(b) deal. Overall, the financing improves near-term funding capacity and signals investor confidence, though leverage metrics will need monitoring once terms are disclosed.

TL;DR: Form D shows compliance with Reg D; minimal governance red flags observed.

The filing adheres to Rule 506(b) requirements and discloses all executive and director relationships. No proceeds are directed to insiders, mitigating conflict-of-interest concerns. Commission disclosure is clear, and the absence of finder’s fees reduces related-party risk. Lack of revenue data limits transparency but is permissible under Reg D. Concentration in a single investor increases influence over company decisions, a point boards should address through covenant management.

Cybin Inc. (CYBN) ha presentato un Modulo D annunciando il completamento di un collocamento privato secondo la Regola 506(b). La società canadese con sede in Ontario specializzata in terapie psichedeliche ha venduto 50 milioni di dollari attraverso un mix di strumenti di debito, warrant/opzioni e azioni sottostanti. La prima vendita è avvenuta il 30 giugno 2025 e l'offerta non si estenderà oltre un anno. L'intero importo previsto è stato collocato, lasciando un residuo pari a 0 dollari.

Termini chiave

  • Dimensione totale dell'offerta: 50.000.000 dollari
  • Tipologia di strumenti: debito e strumenti collegati all'equity
  • Numero di investitori: 1 (stato accreditato non rivelato)
  • Commissioni di vendita: 2.670.000 dollari (Joseph Gunnar & Co., LLC)
  • Commissioni per intermediari: 0 dollari
  • Proventi destinati a insider: 0 dollari

L'emittente non ha rivelato dati su ricavi o patrimonio. Il finanziamento introduce nuovo capitale senza pagamenti immediati a dirigenti o amministratori ed è non collegato a fusioni o acquisizioni. L'esenzione scelta (Regola 506(b)) limita la sollecitazione generale e prevede vendite solo a investitori accreditati o fino a 35 acquirenti sofisticati non accreditati.

Cybin Inc. (CYBN) presentó un Formulario D anunciando la finalización de una colocación privada bajo la Regla 506(b). La empresa de terapias psicodélicas con sede en Ontario vendió 50 millones de dólares mediante una combinación de valores de deuda, warrants/opciones y acciones subyacentes. La primera venta tuvo lugar el 30 de junio de 2025 y la oferta no se extenderá más allá de un año. Se ha colocado la totalidad del monto objetivo, quedando 0 dólares restantes.

Términos clave

  • Tamaño total de la oferta: 50.000.000 dólares
  • Tipo de valores: deuda e instrumentos vinculados a capital
  • Número de inversores: 1 (estatus acreditado no revelado)
  • Comisiones de venta: 2.670.000 dólares (Joseph Gunnar & Co., LLC)
  • Honorarios de intermediarios: 0 dólares
  • Fondos destinados a personas internas: 0 dólares

El emisor no divulgó ingresos ni tamaño de activos. La financiación aporta capital fresco sin pagos inmediatos a ejecutivos o directores y no está vinculada a una fusión o adquisición. La exención seleccionada (Regla 506(b)) restringe la solicitud general y requiere ventas solo a inversores acreditados o hasta 35 compradores sofisticados no acreditados.

Cybin Inc. (CYBN)은 Rule 506(b) 사모 발행 완료를 알리는 Form D를 제출했습니다. 온타리오에 본사를 둔 사이키델릭 치료제 회사는 채무 증권, 워런트/옵션, 기초 주식을 혼합하여 5,000만 달러를 판매했습니다. 첫 판매는 2025년 6월 30일에 이루어졌으며, 공모는 1년을 초과하지 않습니다. 목표 금액 전액이 배정되어 남은 금액은 0달러입니다.

주요 조건

  • 총 공모 규모: 50,000,000달러
  • 증권 유형: 부채 및 주식 연계 상품
  • 투자자 수: 1명 (인증 상태 미공개)
  • 판매 수수료: 2,670,000달러 (Joseph Gunnar & Co., LLC)
  • 중개 수수료: 0달러
  • 내부자 배정 수익: 0달러

발행사는 매출이나 자산 규모를 공개하지 않았습니다. 이번 자금 조달은 경영진이나 이사에게 즉각적인 지급 없이 신규 자본을 추가하며, 합병이나 인수와 관련이 없습니다. 선택된 면제 조항(Rule 506(b))은 일반 모집을 제한하며, 인증 투자자 또는 최대 35명의 비인증 고급 투자자에게만 판매를 허용합니다.

Cybin Inc. (CYBN) a déposé un formulaire D annonçant la clôture d’un placement privé selon la règle 506(b). La société de thérapeutiques psychédéliques basée en Ontario a vendu 50 millions de dollars via un mélange de titres de dette, bons de souscription/options et actions sous-jacentes. La première vente a eu lieu le 30 juin 2025 et l’offre ne s’étendra pas au-delà d’un an. La totalité du montant ciblé a été placée, il reste donc 0 dollar.

Principaux termes

  • Taille totale de l’offre : 50 000 000 dollars
  • Type de titres : dette et instruments liés aux actions
  • Nombre d’investisseurs : 1 (statut accrédité non divulgué)
  • Commissions de vente : 2 670 000 dollars (Joseph Gunnar & Co., LLC)
  • Frais d’apporteurs d’affaires : 0 dollar
  • Produit destiné aux initiés : 0 dollar

L’émetteur a refusé de divulguer ses revenus ou la taille de ses actifs. Ce financement apporte de nouveaux capitaux sans paiements immédiats aux cadres ou administrateurs et n’est pas lié à une fusion ou acquisition. L’exemption choisie (règle 506(b)) restreint la sollicitation générale et exige des ventes uniquement aux investisseurs accrédités ou à un maximum de 35 acheteurs sophistiqués non accrédités.

Cybin Inc. (CYBN) hat ein Formular D eingereicht und die Durchführung einer Privatplatzierung nach Regel 506(b) bekanntgegeben. Das in Ontario ansässige Unternehmen für psychedelische Therapien verkaufte 50 Millionen US-Dollar in einer Mischung aus Schuldtiteln, Warrants/Optionen und zugrunde liegenden Aktien. Der erste Verkauf erfolgte am 30. Juni 2025, und das Angebot wird nicht länger als ein Jahr laufen. Der gesamte Zielbetrag wurde platziert, es verbleiben 0 US-Dollar.

Wichtige Bedingungen

  • Gesamtvolumen des Angebots: 50.000.000 US-Dollar
  • Art der Wertpapiere: Schulden plus aktiengebundene Instrumente
  • Anzahl der Investoren: 1 (Status akkreditiert nicht angegeben)
  • Verkaufsprovisionen: 2.670.000 US-Dollar (Joseph Gunnar & Co., LLC)
  • Vermittlungsgebühren: 0 US-Dollar
  • Erträge für Insider: 0 US-Dollar

Der Emittent verweigerte Angaben zu Umsatz oder Vermögenswerten. Die Finanzierung bringt frisches Kapital ohne sofortige Zahlungen an Führungskräfte oder Direktoren und ist nicht an eine Fusion oder Übernahme gebunden. Die gewählte Befreiung (Regel 506(b)) schränkt die allgemeine Werbung ein und erlaubt Verkäufe nur an akkreditierte Investoren oder bis zu 35 nicht akkreditierte, aber versierte Käufer.

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL
OMB Number: 3235-0076
Estimated average burden
hours per response: 4.00

1. Issuer's Identity

CIK (Filer ID Number) Previous Names
X None
Entity Type
0001833141
X Corporation
Limited Partnership
Limited Liability Company
General Partnership
Business Trust
Other (Specify)

Name of Issuer
CYBIN INC.
Jurisdiction of Incorporation/Organization
ONTARIO, CANADA
Year of Incorporation/Organization
X Over Five Years Ago
Within Last Five Years (Specify Year)
Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer
CYBIN INC.
Street Address 1 Street Address 2
100 King St. West, Suite 5600
City State/Province/Country ZIP/PostalCode Phone Number of Issuer
Toronto ONTARIO, CANADA M5X 1C9 866-292-4601

3. Related Persons

Last Name First Name Middle Name
Drysdale Douglas
Street Address 1 Street Address 2
100 King St. West, Suite 5600
City State/Province/Country ZIP/PostalCode
Toronto ONTARIO, CANADA M5X 1C9
Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):


Last Name First Name Middle Name
Tziras George
Street Address 1 Street Address 2
100 King St. West, Suite 5600
City State/Province/Country ZIP/PostalCode
Toronto ONTARIO, CANADA M5X 1C9
Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):


Last Name First Name Middle Name
So Eric
Street Address 1 Street Address 2
100 King St. West, Suite 5600
City State/Province/Country ZIP/PostalCode
Toronto ONTARIO, CANADA M5X 1C9
Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):


Last Name First Name Middle Name
Fahel Gabriel
Street Address 1 Street Address 2
100 King St. West, Suite 5600
City State/Province/Country ZIP/PostalCode
Toronto ONTARIO, CANADA M5X 1C9
Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):


Last Name First Name Middle Name
Glavine Paul
Street Address 1 Street Address 2
100 King St. West, Suite 5600
City State/Province/Country ZIP/PostalCode
Toronto ONTARIO, CANADA M5X 1C9
Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):


Last Name First Name Middle Name
Cavers Greg
Street Address 1 Street Address 2
100 King St. West, Suite 5600
City State/Province/Country ZIP/PostalCode
Toronto ONTARIO, CANADA M5X 1C9
Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):


Last Name First Name Middle Name
Bartlone Aaron
Street Address 1 Street Address 2
100 King St. West, Suite 5600
City State/Province/Country ZIP/PostalCode
Toronto ONTARIO, CANADA M5X 1C9
Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):


Last Name First Name Middle Name
Firestone Theresa
Street Address 1 Street Address 2
100 King St. West, Suite 5600
City State/Province/Country ZIP/PostalCode
Toronto ONTARIO, CANADA M5X 1C9
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):


Last Name First Name Middle Name
Lawson Mark
Street Address 1 Street Address 2
100 King St. West, Suite 5600
City State/Province/Country ZIP/PostalCode
Toronto ONTARIO, CANADA M5X 1C9
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):


Last Name First Name Middle Name
Froese Grant
Street Address 1 Street Address 2
100 King St. West, Suite 5600
City State/Province/Country ZIP/PostalCode
Toronto ONTARIO, CANADA M5X C19
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):


Last Name First Name Middle Name
Hoskins Eric
Street Address 1 Street Address 2
100 King St. West, Suite 5600
City State/Province/Country ZIP/PostalCode
Toronto ONTARIO, CANADA M5X 1C9
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):


4. Industry Group

Agriculture
Banking & Financial Services
Commercial Banking
Insurance
Investing
Investment Banking
Pooled Investment Fund
Is the issuer registered as
an investment company under
the Investment Company
Act of 1940?
Yes No
Other Banking & Financial Services
Business Services
Energy
Coal Mining
Electric Utilities
Energy Conservation
Environmental Services
Oil & Gas
Other Energy
Health Care
Biotechnology
Health Insurance
Hospitals & Physicians
Pharmaceuticals
Other Health Care
Manufacturing
Real Estate
Commercial
Construction
REITS & Finance
Residential
Other Real Estate
Retailing
Restaurants
Technology
Computers
Telecommunications
Other Technology
Travel
Airlines & Airports
Lodging & Conventions
Tourism & Travel Services
Other Travel
X
Other

5. Issuer Size

Revenue Range OR Aggregate Net Asset Value Range
No Revenues No Aggregate Net Asset Value
$1 - $1,000,000 $1 - $5,000,000
$1,000,001 - $5,000,000 $5,000,001 - $25,000,000
$5,000,001 - $25,000,000 $25,000,001 - $50,000,000
$25,000,001 - $100,000,000 $50,000,001 - $100,000,000
Over $100,000,000 Over $100,000,000
X Decline to Disclose Decline to Disclose
Not Applicable Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii))
Rule 504 (b)(1)(i)
Rule 504 (b)(1)(ii)
Rule 504 (b)(1)(iii)
X Rule 506(b)
Rule 506(c)
Securities Act Section 4(a)(5)
Investment Company Act Section 3(c)
Section 3(c)(1) Section 3(c)(9)
Section 3(c)(2) Section 3(c)(10)
Section 3(c)(3) Section 3(c)(11)
Section 3(c)(4) Section 3(c)(12)
Section 3(c)(5) Section 3(c)(13)
Section 3(c)(6) Section 3(c)(14)
Section 3(c)(7)

7. Type of Filing

X New Notice Date of First Sale 2025-06-30 First Sale Yet to Occur
Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year?
Yes X No

9. Type(s) of Securities Offered (select all that apply)

Equity Pooled Investment Fund Interests
X Debt Tenant-in-Common Securities
X Option, Warrant or Other Right to Acquire Another Security Mineral Property Securities
X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
Yes X No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor $0 USD

12. Sales Compensation

Recipient
Recipient CRD Number None
Joseph Gunnar & Co., LLC 24795
(Associated) Broker or Dealer X None
(Associated) Broker or Dealer CRD Number X None
None None
Street Address 1 Street Address 2
1000 RXR Plaza
City State/Province/Country ZIP/Postal Code
Uniondale NEW YORK 11556
State(s) of Solicitation (select all that apply)
Check "All States" or check individual States
All States
Foreign/non-US
CONNECTICUT

13. Offering and Sales Amounts

Total Offering Amount $50,000,000 USD
or Indefinite
Total Amount Sold $50,000,000 USD
Total Remaining to be Sold $0 USD
or Indefinite

Clarification of Response (if Necessary):

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
1

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions $2,670,000 USD
Estimate
Finders' Fees $0 USD
Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

$0 USD
Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:
  • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
  • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
  • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer Signature Name of Signer Title Date
CYBIN INC. /s/ Douglas Drysdale Douglas Drysdale CEO 2025-07-09

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


FAQ

How much capital did Cybin Inc. (CYBN) raise in the 2025 Form D offering?

Cybin sold $50,000,000 of securities, with no remaining amount to be sold.

What types of securities were issued in Cybin’s private placement?

The offering includes debt instruments, warrants/options, and shares issuable upon warrant exercise.

Which Regulation D exemption did Cybin rely on?

The company claimed Rule 506(b), which limits general solicitation and generally restricts sales to accredited investors.

What sales commissions were paid on the offering?

Cybin disclosed $2,670,000 in commissions to Joseph Gunnar & Co., LLC; no finder’s fees were reported.

How many investors participated in the offering?

The filing lists one investor who purchased the entire $50 million allocation.

Is the financing connected to a merger or acquisition?

No. The filing states the offering is not related to any business combination transaction.

Were any proceeds allocated to Cybin’s executives or directors?

$0 of the gross proceeds are designated for payments to insiders.
Cybin Inc

NYSE:CYBN

CYBN Rankings

CYBN Latest News

CYBN Latest SEC Filings

CYBN Stock Data

182.88M
19.22M
238.24%
41.95%
5.19%
Biotechnology
Healthcare
Link
Canada
Toronto